One piece of fallout from the Pfizer-Wyeth hook up announced a few hours ago is that the latter will not be acquiring Crucell after all.
According to the an online story from the Wall Street Journal, “Crucell NV said Wyeth pulled out of friendly takeover talks with the Dutch vaccine maker.
Crucell admitted the discussions earlier this month, and people familiar with the matter at the time valued Crucell at$1.3 billion.”
A Pizaazz post, written before the Pfizer-Wyeth tie-up was made official and up for about an hour this morning, had speculated the Wyeth-Crucell deal might go ahead regardless of the larger circumstances, but that does not appear to be the case.
We’ve pulled the original post and apologize for speculation that proved to be incorrect.